For in vitro diagnostic use. Others Elecsys SARS-CoV-2 Antigen IVD Elecsys® SARS-CoV-2 Antigen CPS_000623 09345299190 SARS-CoV-2 Ag Elecsys E2G 300 Elecsys SARS-CoV-2 Antigen 07613336193464 Reagents, kits 300 tests cobas e 402/801 true 09345272190 SARS-CoV-2 Ag Elecsys cobas e 200 Elecsys SARS-CoV-2 Antigen 07613336193457 Reagents, kits 200 tests cobas e 411/601/602 true 09345299500 Elecsys SARS-CoV-2 Antigen en 2 FF00000004D5170E FF000000046FEA0E 09345299190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useElecsys SARS‑CoV‑2 Antigen is an immunoassay for the in vitro qualitative detection of the nucleocapsid antigen of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) in nasopharyngeal, oropharyngeal and nasal swab samples from patients with signs and symptoms suggestive of COVID‑19, or known or suspected exposure to SARS‑CoV‑2. The test is intended as an aid in the diagnosis of SARS‑CoV‑2 infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09345299501 Elecsys SARS-CoV-2 Antigen en 1 FF0000000478F00E FF0000000478EF0E 09345299190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useElecsys SARS‑CoV‑2 Antigen is an immunoassay for the in vitro qualitative detection of the nucleocapsid antigen of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) in nasal, nasopharyngeal and oropharyngeal swab samples from patients with signs and symptoms suggestive of COVID‑19, or known or suspected exposure to SARS‑CoV‑2. The test is intended as an aid in the diagnosis of SARS‑CoV‑2 infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09345272500 Elecsys SARS-CoV-2 Antigen en 2 FF00000004D5FE0E FF000000046FF10E 09345272190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useElecsys SARS‑CoV‑2 Antigen is an immunoassay for the in vitro qualitative detection of the nucleocapsid antigen of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) in nasopharyngeal, oropharyngeal and nasal swab samples from patients with signs and symptoms suggestive of COVID‑19, or known or suspected exposure to SARS‑CoV‑2. The test is intended as an aid in the diagnosis of SARS‑CoV‑2 infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09345272501 Elecsys SARS-CoV-2 Antigen en 1 FF0000000478EC0E FF0000000478EB0E 09345272190 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useElecsys SARS‑CoV‑2 Antigen is an immunoassay for the in vitro qualitative detection of the nucleocapsid antigen of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‑CoV‑2) in nasal, nasopharyngeal and oropharyngeal swab samples from patients with signs and symptoms suggestive of COVID‑19, or known or suspected exposure to SARS‑CoV‑2. The test is intended as an aid in the diagnosis of SARS‑CoV‑2 infection.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en